<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2171">
  <stage>Registered</stage>
  <submitdate>24/10/2008</submitdate>
  <approvaldate>24/10/2008</approvaldate>
  <nctid>NCT00788931</nctid>
  <trial_identification>
    <studytitle>A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer</studytitle>
    <scientifictitle>A Phase Ib, Open-label, Two Arm Study of i.v. and Oral Panobinostat (LBH589) in Combination With i.v. Trastuzumab (HerceptinÂ®) and i.v. Paclitaxel as Treatment for Adult Female Patients With HER2 Overexpressing Metastatic Breast Cancer (MBC)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2007-004788-23</secondaryid>
    <secondaryid>CLBH589C2114</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HER-2 Positive Breast Cancer</healthcondition>
    <healthcondition>Metastatic Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - IV LBH589
Treatment: drugs - Oral LBH589
Treatment: drugs - trastuzumab
Treatment: drugs - paclitaxel

Experimental: IV LBH589 + trastuzumab + paclitaxel - i.v. panobinostat

Experimental: Oral LBH589 + trastuzumab + paclitaxel - oral panobinostat


Treatment: drugs: IV LBH589


Treatment: drugs: Oral LBH589


Treatment: drugs: trastuzumab


Treatment: drugs: paclitaxel


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Determine the maximum tolerated dose of oral panobinostat in combination with trastuzumab and paclitaxel. Determine the maximum tolerated dose of iv LBH in combination with trastuzumab and paclitaxel.</outcome>
      <timepoint>At least 21 day cycle for both arms</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability throughout the study for both IV and oral arms to determine the recommended dose for phase ll trials.</outcome>
      <timepoint>4 weeks after end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the efficacy in the expansion phase of the trial when the MTD is defined.</outcome>
      <timepoint>throughout the study and 4 weeks after end of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age &gt; 18 year old

          -  Confirmed HER2+ metastatic breast cancer

          -  Prior treatment and progression on trastuzumab

          -  Patients must have adequate organ functions

          -  Eastern Cooperative Oncology Group (ECOG) performance status of = 1</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients who have had surgery within last 2 weeks prior to starting the treatment

          -  Patients who receive concurrent therapy for brain metastases

          -  Impaired heart function or clinically significant heart disease

          -  Ongoing diarrhea

          -  Liver or renal disease with impaired hepatic or renal functions

          -  Concomitant use of any anti-cancer therapy or certain drugs

          -  Female patients who are pregnant or breast feeding

          -  Patients not willing to use an effective method of birth control Other
             protocol-defined inclusion/exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>15</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Novartis Investigative Site - Woodville</hospital>
    <postcode>5011 - Woodville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>MC</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>PN</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both
      intravenous and oral panobinostat when given in combination with trastuzumab and paclitaxel.
      The study will evaluate safety and efficacy of the combination in adult female patients with
      HER2+ metastatic breast cancer</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00788931</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>